Compare Davita Inc (DVA) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.8. The key difference: Davita Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| DVA | FLRN | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Sector/Thematic |
52-Week High | $235.71 | $30.86 |
52-Week Low | $103.87 | $30.65 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.80 with no recent price movement. The technical outlook is bearish with moving averages signaling caution, though RSI levels suggest potential oversold conditions. Recent institutional buying by Farther Finance Advisors and BCS Wealth Management indicates professional interest. The fund focuses on floating-rate investment grade bonds, positioning it as a potential hedge in the current rising rate environment.
FLRN offers exposure to floating-rate debt securities that may outperform in a rising rate environment. The fund's structure provides inflation protection benefits, but faces headwinds from potential credit quality deterioration and market volatility. Current dividend payments of $0.11 per share provide income support, though the bearish technical signals warrant careful monitoring of market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
